

Focus session: Trial and evidence update

Moderated by J Mandrola (Louisville), F Beyersdorf (Freiburg), N Freemantle (London) |

Saturday 10th October | 10:30–11:45 |

Auditorium, 111–112, 116–117, 118–119, 211, 212

This interactive session focuses on clinical trials and registry data for coronary artery interventions and TAVI. Part 1 covers the role of SYNTAX score in predicting revascularisation strategy and the radial artery as a second CABG conduit. Part 2 focuses on the latest clinical and real-world data on TAVI.

Presentations

PART I Coronary artery interventions

A - SYNTAX score prediction of revascularisation strategy

- 10:30 The SYNTAX score does not predict the outcomes of PCI & CABG | G Biondi-Zoccai
- 10:38 The new 2020 SYNTAX score predicts revascularisation outcomes (PCI vs CABG) | P Serruys
- 10:46 The role of SYNTAX score for treatment decision making. J Brophy | J Brophy
- 10:51 Discussion

B - Radial artery as a second CABG conduit

- 11:01 Longer-term results of the RADIAL database | M Gaudino
- 11:06 10-year results of the RAPCO trial | P Hare
- 11:11 The radial artery is the second graft of choice | T Doenst
- 11:16 Discussion

PART II TAVI & SAVR

- 11:26 Longer-term outcomes of randomised trials: An update | F Barili
- 11:31 PARTNER 3 Trial: An update | V Thourani
- 11:39 TVT Registry: Real world outcomes | J Bavaria
- 11:47 Guidelines recommendations for TAVI | S Kaul
- 11:59 Discussion

You might also be interested in...

A mechanistic investigation of the EDWARDS INTUITY Elite valve's hemodynamic performance

Keywords: aortic stenosis; aortic valve replacement; transvalvular pressure gradients; valve haemodynamics [...]

May 4, 2020

Important safety information:

Use of the EDWARDS INTUITY Elite valve system may be associated with new or worsened conduction disturbances, which may require a permanent cardiac pacemaker implant (PPI). The rate of PPI for the EDWARDS INTUITY Elite valve is within the range reported in the literature for various rapid deployment valves, but higher than that reported for surgical aortic valves. Physicians should assess the benefits and risks of the EDWARDS INTUITY Elite valve prior to implantation. See instructions for use for additional information.

For professional use.

For a listing of indications, contraindications, precautions, warnings, and potential adverse events, please refer to the Instructions for Use (consult eifu.edwards.com where applicable).

Edwards devices placed on the European market meeting the essential requirements referred to in Article 3 of the Medical Device Directive 93/42/EEC bear the CE marking of conformity.

Edwards, Edwards Lifesciences, the stylized E logo, Carpentier-Edwards, EDWARDS INTUITY, EDWARDS INTUITY Elite and PARTNER 3 are trademarks or service marks of Edwards Lifesciences Corporation or its affiliates. All other trademarks are the property of their respective owners.

© 2020 Edwards Lifesciences Corporation. All rights reserved. NP--EU-0156 V1.0

Edwards Lifesciences • Route de l'Etraz 70, 1260 Nyon, Switzerland • edwards.com



Edwards